Appendix 4E - Preliminary final report 30 June 2016
Filed with ASX · · 49 pages · English
Sydney, Australia – 30 August 2016:OncoSil Medical Ltd (ASX: OSL) (Oncosil or theCompany), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to report its financial results for the full year ended 30 June 2016 (the Financial Report) and its Appendix 4E. All financial results are in Australian dollars and are audited. High
Earlier from OncoSil Medical
- Hot Calibration Run of the OncoSil Device
- FDA IDE Approval
- Regulatory Update June 2016
- OncoSil Medical Appoints Global Sales and Marketing Director
- Appendix 4C - Quarterly Cashflow
Later from OncoSil Medical
- Receipt of $2.3m R & D Tax Incentive Refund
- Pancreatic cancer clinical study update
- Appendix 4C - Quarterly Cash Flow
- Ethics Approval for OncoPac Clinical Study
- MHRA Approval to commence study in UK
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical